Press Releases 2023

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO™ to redefine expectations for treatment of children <12 years of age with hemophilia A

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Media Update: New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression 

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants

Press Release: Sanofi announces change in R&D leadership

Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes